In Zomedica's case, the company only began selling its flagship Truforma platform, which helps veterinarians run tests on animals more efficiently than other diagnostic products, earlier this year. This business falls into both of those categories. And while Zomedica may not turn out to be a bad buy, there are two things to be wary of: A company that generates little to no revenue and that spends excessively. But that hasn't stopped retail investors from piling money into it shares of the company are up more than 570% over the past year (the S&P 500 has risen by just 32% during that time). ![]() Veterinary health company Zomedica is a business that's in its very early stages.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |